{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:32:19Z","timestamp":1793640739839,"version":"4.5.1"},"reference-count":47,"publisher":null,"issue":"4","license":[{"start":{"date-parts":[[2020,5,4]],"date-time":"2020-05-04T00:00:00Z","timestamp":1588550400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/lib.ossn.ru\/jour\/about\/editorialPolicies#openAccessPolicy"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kardiologiia"],"abstract":"<jats:p>The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients\u2019 age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system.<\/jats:p>","DOI":"10.18087\/cardio.2020.4.n1122","type":"journal-article","created":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T05:14:45Z","timestamp":1589260485000},"page":"4-9","source":"Crossref","is-referenced-by-count":6,"title":["Role of age, comorbidity and renin- angiotensin-aldosterone system in COVID-19. Effects of ACE inhibitors and angiotensin receptor blockers"],"prefix":"10.68900","volume":"60","author":[{"given":"Yu. V.","family":"Mareev","sequence":"first","affiliation":[{"name":"National Medical Research Center for Therapy and Preventive Medicine, Petroverigsky Per. 10, Bldg. 3, Moscow 101990"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7285-2048","authenticated-orcid":true,"given":"V. Yu.","family":"Mareev","sequence":"additional","affiliation":[{"name":"Medical Scientific-Educational Canter of MSU n. a. M. V. Lomonosov, Moscow"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":null,"published-online":{"date-parts":[[2020,5,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Lakatta EG, Levy D. Arterial and Cardiac Aging: Major Shareholders in Cardiovascular Disease Enterprises: Part II: The Aging Heart in Health: Links to Heart Disease. Circulation. 2003;107(2):346\u201354. DOI: 10.1161\/01.CIR.0000048893.62841.F7","DOI":"10.1161\/01.CIR.0000048893.62841.F7"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus\u2013induced lung injury. Nature Medicine. 2005;11(8):875\u20139. DOI: 10.1038\/nm1267","DOI":"10.1038\/nm1267"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Hoffmann M, Kleine-Weber H, Schroeder S, Kr\u00fcger N, Herrler T, Erichsen S et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181(2):271-280.e8. DOI: 10.1016\/j.cell.2020.02.052","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Lakatta EG. The reality of getting old. Nature Reviews Cardiology. 2018;15(9):499\u2013500. DOI: 10.1038\/s41569-018-0068-y","DOI":"10.1038\/s41569-018-0068-y"},{"key":"ref5","unstructured":"Belenkov Yu.N., Mareev V.Yu. Principles of rational treatment of chronic heart failure. -M.: Media Medika;2000. \u2013 266 p. [Russian: Belenkov Yu.N., Mareev V.Yu. Printsipy ratsional'nogo lecheniya khronicheskoi serdechnoi nedostatochnosti. -M.: Media Medika; 2000. \u2013 266s]"},{"key":"ref6","unstructured":"Skvortsov A.A., Nasonova S.N., Sychev A.V., Arbolishvili G.N., Baklanova N.A., Mareev V.Yu. et al. Combined therapy with quinapril, an ace inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect of monotherapy (data from the trial SADKO-CHF). Therapeutic Archive. 2005;77(8):34\u201343. [Russian: Skvortsov A.A., Nasonova S.N., Sychev A.V., Arbolishvili G.N., Baklanova N.A., Mareev V.Yu. i dr. Kombinirovannoe primenenie ingibitora angiotenzinprevrashchayushchego fermenta kvinaprila i blokatora retseptorov 1-go tipa k angiotenzinu II valsartana u bol'nykh s umerennoi khronicheskoi serdechnoi nedostatochnost'yu: vozmozhno li povyshenie stepeni neirogormonal'noi blokady i uluchshenie parametrov sutochnoi variabel'nosti ritma serdtsa po sravneniyu s deistviem monoterapii (po rezul'tatam issledovaniya SADKO-KhSN). Terapevticheskii arkhiv. 2005;77(8):34-43]"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"AlGhatrif M, Cingolani O, Lakatta EG. The Dilemma of Coronavirus Disease 2019, Aging, and Cardiovascular Disease: Insights from Cardiovascular Aging Science. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001\/jamacardio.2020.1329","DOI":"10.1001\/jamacardio.2020.1329"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Arnold AC, Gallagher PE, Diz DI. Brain renin\u2013angiotensin system in the nexus of hypertension and aging. Hypertension Research. 2013;36(1):5\u201313. DOI: 10.1038\/hr.2012.161","DOI":"10.1038\/hr.2012.161"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Xudong X, Junzhu C, Xingxiang W, Furong Z, Yanrong L. Age- and gender-related difference of ACE2 expression in rat lung. Life Sciences. 2006;78(19):2166\u201371. DOI: 10.1016\/j.lfs.2005.09.038","DOI":"10.1016\/j.lfs.2005.09.038"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Schouten LR, van Kaam AH, Kohse F, Veltkamp F, Bos LD, de Beer FM et al. Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study. Annals of Intensive Care. 2019;9(1):55. DOI: 10.1186\/s13613-019-0529-4","DOI":"10.1186\/s13613-019-0529-4"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Science China Life Sciences. 2020;63(3):364\u201374. DOI: 10.1007\/s11427-020-1643-8","DOI":"10.1007\/s11427-020-1643-8"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Liang W, Zhu Z, Guo J, Liu Z, He X, Zhou W et al. Severe Acute Respiratory Syndrome, Beijing, 2003. Emerging Infectious Diseases. 2004;10(1):25\u201331. DOI: 10.3201\/eid1001.030553","DOI":"10.3201\/eid1001.030553"},{"key":"ref13","unstructured":"Backhaus A. Coronavirus: Why it\u2019s so deadly in Italy. Medium. 2020; [Internet. Av. at: https:\/\/medium.com\/@andreasbackhausab\/coronavirus-why-its-so-deadly-in-italy-c4200a15a7bf]"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; [Epub ahead of print]. DOI: 10.1001\/jama.2020.5394","DOI":"10.1001\/jama.2020.5394"},{"key":"ref15","unstructured":"Official website of the Mayor of Moscow. Coronavirus: official information. Av. at: https:\/\/www.mos.ru\/city\/projects\/covid-19\/. 2020. [Russian: Ofitsial'nyi sait Mera Moskvy. Koronavirus: ofitsial'naya informatsiya. Dostupno na: https:\/\/www.mos.ru\/city\/projects\/covid-19\/. 2020.]"},{"key":"ref16","unstructured":"China: age distribution of novel coronavirus patients 2020. [Internet] Available at: https:\/\/www.statista.com\/statistics\/1095024\/china-age-distribution-of-wuhan-coronavirus-covid-19-patients\/"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Wu Z, McGoogan JM. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239. DOI: 10.1001\/jama.2020.2648","DOI":"10.1001\/jama.2020.2648"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054\u201362. DOI: 10.1016\/S0140-6736(20)30566-3","DOI":"10.1016\/S0140-6736(20)30566-3"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Watkins J. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ. 2020;m810. [Av. at: https:\/\/www.bmj.com\/content\/368\/bmj.m810\/rr-2]. DOI: 10.1136\/bmj.m810","DOI":"10.1136\/bmj.m810"},{"key":"ref20","unstructured":"Phadke MA. Use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections \u2013 Novel mode of treatment. BMJ. 2020; [Av. at: https:\/\/www.bmj.com\/content\/368\/bmj.m406\/rr-2]"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors in Patients with Covid-19. New England Journal of Medicine. 2020;NEJMsr2005760. [Epub ahead of print]. DOI: 10.1056\/NEJMsr2005760","DOI":"10.1056\/NEJMsr2005760"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Roca-Ho H, Riera M, Palau V, Pascual J, Soler M. Characterization of ACE and ACE2 Expression within Different Organs of the NOD Mouse. International Journal of Molecular Sciences. 2017;18(3):563. DOI: 10.3390\/ijms18030563","DOI":"10.3390\/ijms18030563"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2. Circulation. 2005;111(20):2605\u201310. DOI: 10.1161\/CIRCULATIONAHA.104.510461","DOI":"10.1161\/CIRCULATIONAHA.104.510461"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M et al. Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted Rat. Hypertension. 2006;48(4):572\u20138. DOI: 10.1161\/01.HYP.0000237862.94083.45","DOI":"10.1161\/01.HYP.0000237862.94083.45"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ishiyama Y, Gallagher PE, Averill DB, Tallant EA, Brosnihan KB, Ferrario CM. Upregulation of Angiotensin-Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin II Receptors. Hypertension. 2004;43(5):970\u20136. DOI: 10.1161\/01.HYP.0000124667.34652.1a","DOI":"10.1161\/01.HYP.0000124667.34652.1a"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hamming I, Van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats: Renal ACE and ACE2 during ACE inhibition and low salt. Experimental Physiology. 2008;93(5):631\u20138. DOI: 10.1113\/expphysiol.2007.041855","DOI":"10.1113\/expphysiol.2007.041855"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Burchill LJ, Velkoska E, Dean RG, Griggs K, Patel SK, Burrell LM. Combination renin\u2013angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions. Clinical Science. 2012;123(11):649\u201358. DOI: 10.1042\/CS20120162","DOI":"10.1042\/CS20120162"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K et al. Urinary Angiotensin-Converting Enzyme 2 in Hypertensive Patients May Be Increased by Olmesartan, an Angiotensin II Receptor Blocker. American Journal of Hypertension. 2015;28(1):15\u201321. DOI: 10.1093\/ajh\/hpu086","DOI":"10.1093\/ajh\/hpu086"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. International Journal of Oral Science. 2020;12(1):8. DOI: 10.1038\/s41368-020-0074-x","DOI":"10.1038\/s41368-020-0074-x"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Perico L, Benigni A, Remuzzi G. Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade. Nephron. 2020;1\u20139. [Epub ahead of print]. DOI: 10.1159\/000507305","DOI":"10.1159\/000507305"},{"key":"ref31","unstructured":"Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients with COVID-19. ClinicalTrials.gov Identifier: NCT04287686. 2020. [Av. at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04287686]"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Guo J, Huang Z, Lin L, Lv J. Coronavirus Disease 2019 (COVID\u201019) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin\u2010Converting Enzyme Inhibitors\/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Journal of the American Heart Association. 2020;9(7):e016219. DOI: 10.1161\/JAHA.120.016219","DOI":"10.1161\/JAHA.120.016219"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J et al. Association of Inpatient Use of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized with COVID-19. Circulation Research. 2020; [Epub ahead of print]. DOI: 10.1161\/CIRCRESAHA.120.317134","DOI":"10.1161\/CIRCRESAHA.120.317134"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Bean D, Kraljevic Z, Searle T, Bendayan R, Pickles A, Folarin A et al. Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute Hospital Trust. DOI: 10.1101\/2020.04.07.20056788 [Av. at: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.04.07.20056788]. 2020.","DOI":"10.1101\/2020.04.07.20056788"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Liu Y, Huang F, Xu J, Yang P, Qin Y, Cao M et al. Anti-hypertensive Angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients. DOI: 10.1101\/2020.03.20.20039586 [Av. at: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.03.20.20039586]. 2020.","DOI":"10.1101\/2020.03.20.20039586"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Yang G, Tan Z, Zhou L, Yang M, Peng L, Liu J et al. Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors Usage is Associated with Improved Inflammatory Status and Clinical Outcomes in COVID-19 Patients with Hypertension. DOI: 10.1101\/2020.03.31.20038935 [Av. at: http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.03.31.20038935]. 2020.","DOI":"10.1101\/2020.03.31.20038935"},{"key":"ref37","unstructured":"Losartan for Patients with COVID-19 Requiring Hospitalization. 2020. ClinicalTrials.gov Identifier: NCT04312009. [Internet] Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04312009"},{"key":"ref38","unstructured":"Losartan for Patients with COVID-19 Not Requiring Hospitalization. 2020. ClinicalTrials.gov Identifier: NCT04311177. [Internet] Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04311177"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260\u2013e4260. DOI: 10.1136\/bmj.e4260","DOI":"10.1136\/bmj.e4260"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus\u2013Infected Pneumonia in Wuhan, China. JAMA. 2020;323(11):1061\u20139. DOI: 10.1001\/jama.2020.1585","DOI":"10.1001\/jama.2020.1585"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovascular Research. 2020;cvaa078. [Epub ahead of print]. DOI: 10.1093\/cvr\/cvaa078","DOI":"10.1093\/cvr\/cvaa078"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiology. 2020; [Epub ahead of print]. DOI: 10.1001\/jamacardio.2020.1286","DOI":"10.1001\/jamacardio.2020.1286"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin. European Heart Journal. 2020;ehaa190. [Epub ahead of print]. DOI: 10.1093\/eurheartj\/ehaa190","DOI":"10.1093\/eurheartj\/ehaa190"},{"key":"ref44","unstructured":"Guidelines for the diagnosis and treatment of diseases of the circulatory system (CCS) in the context of the COVID-19 pandemic. Av. at: https:\/\/scardio.ru\/news\/novosti_obschestva\/rukovodstvo_po_diagnostike_i_lecheniyu_bolezney_sistemy_krovoobrascheniya_bsk_v_kontekste_pandemii_covid19\/. 2020. [Russian: Rukovodstvo po diagnostike i lecheniyu boleznei sistemy krovoobrashcheniya (BSK) v kontekste pandemii COVID-19. Dostupno na: https:\/\/scardio.ru\/news\/novosti_obschestva\/rukovodstvo_po_diagnostike_i_lecheniyu_bolezney_sistemy_krovoobrascheniya_bsk_v_kontekste_pandemii_covid19\/. 2020]"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Oudit GY, Kassiri Z, Jiang C, Liu PP, Poutanen SM, Penninger JM et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. European Journal of Clinical Investigation. 2009;39(7):618\u201325. DOI: 10.1111\/j.1365-2362.2009.02153.x","DOI":"10.1111\/j.1365-2362.2009.02153.x"},{"key":"ref46","unstructured":"De Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. Av. at: https:\/\/www.escardio.org\/Councils\/Council-on-Hypertension-(CHT)\/News\/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang. 2020."},{"key":"ref47","unstructured":"American College of Cardiology. HFSA\/ACC\/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. Av. at: https:\/\/www.acc.org\/latest-in-cardiology\/articles\/2020\/03\/17\/08\/59\/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19. 2020."}],"container-title":["Kardiologiia"],"original-title":[],"link":[{"URL":"https:\/\/lib.ossn.ru\/jour\/article\/viewFile\/1122\/656","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:17:35Z","timestamp":1793639855000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardio.elpub.ru\/jour\/article\/view\/1122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,4]]},"references-count":47,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,5,4]]}},"URL":"https:\/\/doi.org\/10.18087\/cardio.2020.4.n1122","relation":{},"ISSN":["2412-5660","0022-9040"],"issn-type":[{"value":"2412-5660","type":"electronic"},{"value":"0022-9040","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,4]]}}}